Teligent Gets Two FDA Approvals For Its Topical Prescription Portfolio

Teligent, Inc.

disclosed that it received approvals from the U.S. Food and Drug Administration (FDA) for its abbreviated new drug applications (ANDAs) for both Triamcinolone Acetonide Lotion USP, 0.1%, as well as, Triamcinolone Acetonide Lotion USP, 0.025%. according to the company, the FDA has approved seven ANDAs now from its internally developed pipeline of topical generic pharmaceutical products. Teligent quoted IMS Health data of May indicated that the total addressable market for these two products was about $6.8 million. The company's president and CEO, Jason Grenfell-Gardner, said, "We are excited to add these two new products to our growing portfolio of topical prescription medicines. We have now received six approvals from the FDA this year, including an earlier approval of a partnered submission. Our team is committed to bringing these products to market this quarter.'' Shares of the company traded 1.76 percent higher on Friday.